Natera Publishes Results From Prospective, Multicenter Study In Merkel Cell Carcinoma In The JAMA Dermatology Journal; Signatera Test Was A Significantly Stronger Predictor Of Recurrence Than AMERK
The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected relapse earlier.MCC is a
Natera's Signatera test proved better than a competing test at predicting if Merkel cell cancer will come back, and it spotted problems earlier. This suggests the company's tool is more useful for doctors, which could help more patients trust and use it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.